Stiffness-tunable oral nanoparticles facilitate damaged islet β cell restoration for diabetes treatment
Science Advances · 2026
DOI: 10.1126/sciadv.aed0407 ↗At a glance
Journal article in Science Advances, 2026. Written by Wenyan She and 5 co-authors. Institution: School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China. Major MEDLINE topics: Nanoparticles, Insulin-Secreting Cells, Diabetes Mellitus, Experimental. Cited 1 times so far (Crossref); 59 references. The full text is freely available in PubMed Central. Funded by: National Natural Science Foundation of China, Natural Science Foundation of Henan Province, Program for Innovative Research Team (in Science and Technology) in University of Henan Province.
Topics: Diabetes mellitus
Abstract (original language)
Diabetes mellitus remains a global health challenge, as current insulin-based therapies merely control blood glucose without restoring islet β cell function, leaving patients dependent on lifelong medication and vulnerable to hypoglycemia. Antioxidant drugs hold promise for islet β cell repair but are limited by poor gastrointestinal transportation and insufficient pancreatic targetability. Here, we initially identify ferroptosis-associated oxidative stress as a key cause of islet β cell death and develop six stiffness-gradient nanoparticles by embedding bent oleic acid into ordered 1,2-distearoyl- sn -glycero-3-phosphoethanolamine to enhance drug bioavailability. Nanoparticles with intermediate stiffness optimize membrane wrapping and minimize energetic cost, enhancing intestinal M cell transcytosis and macrophage-mediated hitchhiking, thereby increasing pancreatic curcumin accumulation by ~4.5-fold. In diabetic models, this formulation suppresses ferroptosis-associated oxidative stress, promotes in situ islet β cell repair, and restores insulin homeostasis and autonomous glycemic control, maintaining normoglycemia without hypoglycemia even after treatment cessation. This study represents a patient-friendly oral nanotherapy that outperforms insulin therapy in long-standing diabetes management.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
- Henan Key Laboratory of Nanomedicine for Targeting Diagnosis and Treatment, Zhengzhou University, Zhengzhou 450001, China.
- State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, Zhengzhou University, Zhengzhou 450001, China.
ORCID profiles: Wenyan She, Xiaojuan Jiang, Lin Hou
Funding
- National Natural Science Foundation of China
- Natural Science Foundation of Henan Province
- Program for Innovative Research Team (in Science and Technology) in University of Henan Province
- Science and Technology R&D Plan Joint Fund of Henan Province
- Zhongyuan Sci-Tech Innovation Leading Talents
- Postdoctoral Fellowship Program (Grade B) of China Postdoctoral Science Foundation
Cite
APA
She, W., Jiang, X., Deng, S., Hu, L., Huang, C., & Hou, L. (2026). Stiffness-tunable oral nanoparticles facilitate damaged islet β cell restoration for diabetes treatment. Science Advances. https://doi.org/10.1126/sciadv.aed0407
Vancouver
She W, Jiang X, Deng S, Hu L, Huang C, Hou L. Stiffness-tunable oral nanoparticles facilitate damaged islet β cell restoration for diabetes treatment. Science Advances. 2026. doi:10.1126/sciadv.aed0407
BibTeX
@article{She2026,
author = {She, Wenyan and Jiang, Xiaojuan and Deng, Siying and Hu, Luyuan and Huang, Chenxi and Hou, Lin},
title = {Stiffness-tunable oral nanoparticles facilitate damaged islet β cell restoration for diabetes treatment},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aed0407}
}
EUVIMED